Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
Thompson PL, Aylward PE, Federman J, Giles RW, Harris PJ, Hodge RL, Nelson GI, Thomson A, Tonkin AM, Walsh WF. Thompson PL, et al. Among authors: aylward pe. Circulation. 1991 May;83(5):1534-42. doi: 10.1161/01.cir.83.5.1534. Circulation. 1991. PMID: 1902404 Clinical Trial.
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial.
White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, Kleiman NS, Aylward PE, Gore JM, Vahanian A, Lee KL, Ross AM, Topol EJ. White HD, et al. Among authors: aylward pe. Circulation. 1996 Oct 15;94(8):1826-33. doi: 10.1161/01.cir.94.8.1826. Circulation. 1996. PMID: 8873656 Clinical Trial.
Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Tardiff BE, Califf RM, Morris D, Bates E, Woodlief LH, Lee KL, Green C, Rutsch W, Betriu A, Aylward PE, Topol EJ. Tardiff BE, et al. Among authors: aylward pe. J Am Coll Cardiol. 1997 Feb;29(2):240-9. doi: 10.1016/s0735-1097(96)00492-5. J Am Coll Cardiol. 1997. PMID: 9014973 Free article. Clinical Trial.
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
White HD, Aylward PE, Frey MJ, Adgey AA, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B. White HD, et al. Among authors: aylward pe. Circulation. 1997 Oct 7;96(7):2155-61. doi: 10.1161/01.cir.96.7.2155. Circulation. 1997. PMID: 9337184 Clinical Trial.
Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries.
Betriu A, Califf RM, Bosch X, Guerci A, Stebbins AL, Barbagelata NA, Aylward PE, Vahanian A, Van de Werf F, Topol EJ. Betriu A, et al. Among authors: aylward pe. J Am Coll Cardiol. 1998 Jan;31(1):94-102. doi: 10.1016/s0735-1097(97)00428-2. J Am Coll Cardiol. 1998. PMID: 9426024 Free article.
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Zabel KM, Granger CB, Becker RC, Bovill EG, Hirsh J, Aylward PE, Topol EJ, Califf RM. Zabel KM, et al. Among authors: aylward pe. Am Heart J. 1998 Nov;136(5):868-76. doi: 10.1016/s0002-8703(98)70133-4. Am Heart J. 1998. PMID: 9812083 Clinical Trial.
213 results